Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis

被引：0
|
作者：
Porter, J
Borgna-Pignatti, C
Baccarani, M
Saviano, A
Abish, S
Malizia, R
Nick, H
Opitz, H
Rabault, B
Gathmann, I
Marks, P
机构：
[1] Univ Coll Hosp, London, England
[2] Univ Ferrara, I-44100 Ferrara, Italy
[3] Policlin S Orsola, Bologna, Italy
[4] Azienda Ospe Rilievo Nazl A Cararelli, Naples, Italy
[5] Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada
[6] Azienda Ospe Villa Sofia, Palermo, Italy
[7] Novartis, Basel, Switzerland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2690
引用
下载
收藏
页码：755A / 756A
页数：2
相关论文
共 50 条
  • [21] Deferasirox (ICL670) for the treatment of chronic iron overload in patients with β-thalassemia
    Piraino, B.
    Calabro, A.
    Muscolino, G.
    La Rosa, M.
    Rigoli, L.
    Gallizzi, R.
    Salpietro, D. C.
    ACTA PAEDIATRICA, 2007, 96 : 129 - 129
  • [22] Cost-effectiveness analysis of oral iron chelation therapy with deferasirox (Exjade®, ICL670) versus infusional chelation therapy with deferoxamine in patients with transfusion-dependent myelodysplastic
    Delea, TE
    Thomas, SK
    Baladi, JF
    Phatak, PD
    BLOOD, 2005, 106 (11) : 484B - 485B
  • [23] Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD):: Comparison between deferasirox (Exjade®, ICL670) and deferoxamine (DFO).
    Vichinsky, E
    Fischer, R
    Pakbaz, Z
    Onyekwere, O
    Porter, J
    Swerdlow, P
    Coates, T
    Lane, P
    Files, B
    Mueller, BU
    Coïc, L
    Forni, G
    Abetz, L
    Baladi, JF
    Ressayre-Djaffer, C
    Gathmann, I
    Alberti, D
    Marks, P
    BLOOD, 2005, 106 (11) : 656A - 657A
  • [24] Once-daily, oral chelation with deferasirox (Exjade®, ICL670) provides sustained protection from labile plasma iron in 2-thalassemia patients
    Daar, S.
    Taher, A.
    Pathare, A.
    Nick, H.
    Krahn, U.
    Hadler, D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 513 - 514
  • [25] Deferasirox (ICL670; Exjade®) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS)
    List, Alan F.
    Baer, M. R.
    Steensma, D.
    Raza, A.
    Esposito, J.
    Virkus, J.
    Feigert, J.
    Besa, E.
    Paley, C.
    BLOOD, 2007, 110 (11) : 440A - 440A
  • [26] Oral deferasirox (Exjade®, ICL670) is effective, with a clinically manageable safety profile, in pediatric β-thalassemia patients with high iron burden
    Taber, Ali
    Al Jefri, Abdullah
    Elalfy, Mollsen Saleh
    Al Zir, Kusai
    Daar, Shahina
    Damanhouri, Ghazi
    Kriemler-Krahn, Ulrike
    Pfluger, Dietrich
    Hadler, Dominik
    El-Beshlawy, Aural
    BLOOD, 2007, 110 (11) : 817A - 817A
  • [27] Randomized phase II trial of deferasirox (Exjade•, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload
    Piga, Antonio
    Galanello, Renzo
    Forni, Gian Luca
    Cappellini, Maria Domenica
    Origa, Raffaella
    Zappu, Antonietta
    Donato, Guido
    Bordone, Elena
    Lavagetto, Antonella
    Zanaboni, Laura
    Sechaud, Rornain
    Hewson, Nicola
    Ford, John M.
    Opitz, Herbert
    Alberti, Daniele
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (07): : 873 - 880
  • [28] Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia.
    Brissot, P
    Turlin, B
    Forni, GL
    Alimena, G
    Quarta, G
    Selleslag, D
    Thompson, A
    Locatelli, F
    Berretta, A
    de Montalembert, M
    Ressayre-Djaffer, C
    Rabault, B
    Ford, J
    Alberti, D
    BLOOD, 2005, 106 (11) : 242A - 243A
  • [29] Evaluation of deferasirox (Exjade®, ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) ≤1000 ng/mL in long-term studies
    Cappellini, Maria Domenica
    Vichinsky, Elliott
    Ford, John M.
    Rabault, Bertrand
    Porter, John
    BLOOD, 2007, 110 (11) : 16B - 16B
  • [30] Summary of long-term renal safety data in transfused patients with secondary iron overload receiving deferasirox (Exjade®, ICL670).
    Bennett, W.
    Ponticelli, C.
    Piga, A.
    Kattamis, A.
    Glimm, E.
    Ford, J.
    BLOOD, 2006, 108 (11) : 30B - 30B
12345